Canada Life’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $19M | Sell |
57,255
-624
| -1% | -$212K | 0.03% | 379 |
|
|
2025
Q4 | $23M | Sell |
57,879
-35,213
| -38% | -$15.6M | 0.04% | 341 |
|
|
2025
Q3 | $41.6M | Buy |
93,092
+1,938
| +2% | +$789K | 0.06% | 279 |
|
|
2025
Q2 | $29.7M | Buy |
91,154
+7,326
| +9% | +$2.03M | 0.05% | 327 |
|
|
2025
Q1 | $22.7M | Buy |
83,828
+6,909
| +9% | +$1.78M | 0.04% | 379 |
|
|
2024
Q4 | $18.1M | Buy |
76,919
+8,206
| +12% | +$2.16M | 0.03% | 444 |
|
|
2024
Q3 | $18.9M | Buy |
68,713
+14,308
| +26% | +$3.73M | 0.03% | 427 |
|
|
2024
Q2 | $13.2M | Buy |
54,405
+6,860
| +14% | +$1.08M | 0.02% | 496 |
|
|
2024
Q1 | $7.11M | Buy |
47,545
+1,804
| +4% | +$301K | 0.01% | 659 |
|
|
2023
Q4 | $8.7M | Buy |
45,741
+1,568
| +4% | +$267K | 0.02% | 569 |
|
|
2023
Q3 | $7.82M | Sell |
44,173
-764
| -2% | -$146K | 0.02% | 582 |
|
|
2023
Q2 | $8.59M | Buy |
44,937
+1,928
| +4% | +$382K | 0.02% | 556 |
|
|
2023
Q1 | $8.63M | Buy |
43,009
+700
| +2% | +$147K | 0.02% | 567 |
|
|
2022
Q4 | $10.1M | Sell |
42,309
-308
| -0.7% | -$65.7K | 0.03% | 518 |
|
|
2022
Q3 | $8.51M | Sell |
42,617
-7,367
| -15% | -$1.41M | 0.02% | 549 |
|
|
2022
Q2 | $7.29M | Sell |
49,984
-12,385
| -20% | -$1.76M | 0.02% | 600 |
|
|
2022
Q1 | $10.8M | Buy |
62,369
+10,892
| +21% | +$1.66M | 0.02% | 559 |
|
|
2021
Q4 | $8.71M | Sell |
51,477
-15,739
| -23% | -$2.93M | 0.02% | 626 |
|
|
2021
Q3 | $12.8M | Sell |
67,216
-3,652
| -5% | -$685K | 0.03% | 511 |
|
|
2021
Q2 | $12M | Sell |
70,868
-8,697
| -11% | -$1.27M | 0.03% | 546 |
|
|
2021
Q1 | $11.2M | Buy |
79,565
+7,045
| +10% | +$1.06M | 0.03% | 572 |
|
|
2020
Q4 | $9.41M | Buy |
72,520
+11,676
| +19% | +$1.56M | 0.02% | 632 |
|
|
2020
Q3 | $8.85M | Sell |
60,844
-627
| -1% | -$89.1K | 0.02% | 560 |
|
|
2020
Q2 | $9.06M | Buy |
61,471
+15,382
| +33% | +$2.07M | 0.02% | 541 |
|
|
2020
Q1 | $5.05M | Buy |
46,089
+88
| +0.2% | +$10.2K | 0.01% | 625 |
|
|
2019
Q4 | $5.26M | Buy |
+46,001
| New | +$4.59M | 0.01% | 706 |
|
|
2019
Q3 | – | Sell |
-42,171
| Closed | -$3.06M | – | 1153 |
|
|
2019
Q2 | $3.06M | Sell |
42,171
-10,241
| -20% | -$786K | 0.01% | 946 |
|
|
2019
Q1 | $4.89M | Buy |
52,412
+13,287
| +34% | +$1.11M | 0.01% | 661 |
|
|
2018
Q4 | $2.73M | Sell |
39,125
-155
| -0.4% | -$11.9K | 0.01% | 857 |
|
|
2018
Q3 | $3.44M | Sell |
39,280
-8,926
| -19% | -$898K | 0.01% | 852 |
|
|
2018
Q2 | $4.75M | Buy |
48,206
+1,685
| +4% | +$167K | 0.01% | 728 |
|
|
2018
Q1 | $5.55M | Buy |
46,521
+16,159
| +53% | +$2.08M | 0.01% | 686 |
|
|
2017
Q4 | $3.85M | Buy |
30,362
+21,458
| +241% | +$2.7M | 0.01% | 800 |
|
|
2017
Q3 | $1.05M | Buy |
8,904
+695
| +8% | +$59.3K | ﹤0.01% | 1499 |
|
|
2017
Q2 | $653K | Hold |
8,209
| – | – | ﹤0.01% | 1641 |
|
|
2017
Q1 | $420K | Sell |
8,209
-17,687
| -68% | -$817K | ﹤0.01% | 1748 |
|
|
2016
Q4 | $973K | Sell |
25,896
-14,994
| -37% | -$628K | ﹤0.01% | 1490 |
|
|
2016
Q3 | $2.77M | Hold |
40,890
| – | – | 0.01% | 877 |
|
|
2016
Q2 | $2.26M | Buy |
40,890
+188
| +0.5% | +$11.8K | 0.01% | 953 |
|
|
2016
Q1 | $2.55M | Buy |
40,702
+4,469
| +12% | +$297K | 0.01% | 695 |
|
|
2015
Q4 | $3.41M | Buy |
36,233
+239
| +0.7% | +$22.2K | 0.01% | 657 |
|
|
2015
Q3 | $2.9M | Buy |
35,994
+24,151
| +204% | +$2.68M | 0.01% | 670 |
|
|
2015
Q2 | $1.42M | Buy |
11,843
+5,526
| +87% | +$660K | ﹤0.01% | 866 |
|
|
2015
Q1 | $658K | Buy |
6,317
+900
| +17% | +$91.2K | ﹤0.01% | 948 |
|
|
2014
Q4 | $524K | Buy |
5,417
+1,118
| +26% | +$104K | ﹤0.01% | 959 |
|
|
2014
Q3 | $337K | Hold |
4,299
| – | – | ﹤0.01% | 1025 |
|
|
2014
Q2 | $270K | Hold |
4,299
| – | – | ﹤0.01% | 1014 |
|
|
2014
Q1 | $287K | Hold |
4,299
| – | – | ﹤0.01% | 985 |
|
|
2013
Q4 | $278K | Buy |
+4,299
| New | +$256K | ﹤0.01% | 980 |
|
Other funds holding ALNY
VPM
VCM
Canada Life's ALNY Position: Q1 2026 in Review
Canada Life reduced its Alnylam Pharmaceuticals (ALNY) stake by 1.1% in Q1 2026, selling an estimated $212K and leaving 57,255 shares worth $19M. The position accounts for 0.03% of the portfolio, ranked #379.
Canada Life first reported a position in ALNY in Q4 2013 and has held it in 49 quarters since. The position peaked at $41.6M in Q3 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.
- Canada Life held 57,255 shares of Alnylam Pharmaceuticals worth $19M as of Q1 2026.
- Canada Life sold 624 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $212K.
- Alnylam Pharmaceuticals made up 0.03% of Canada Life's portfolio in Q1 2026, its #379 holding.
- Canada Life first reported a position in Alnylam Pharmaceuticals in Q4 2013 and has held it in 49 quarters since.
- Canada Life's Alnylam Pharmaceuticals position peaked at $41.6M in Q3 2025.
- 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.
Based on Canada Life's 13F filing for Q1 2026, filed 14 May 2026.